Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK0O7U)

• Drug Name: Flutamide Drug Info
• Synonyms: Apimid; ApoFlutamide; Cebatrol; Chimax; Cytamid; Drogenil; Eulexin; Eulexine; Fluken; Flulem; Flumid; FlutaGRY; Flutacell; Flutamida; Flutamidum; Flutamin; Flutandrona; Flutaplex; Flutexin; Fugerel; METHOXYCHLOR; NFBA; Niftholide; Niftolid; Niftolide; NovoFlutamide; Odyne; Oncosal; Prostacur; Prostandril; Prostica; Prostogenat; Testotard; Alphapharm Brand of Flutamide; Apo Flutamide; Apogepha Brand of Flutamide; Apotex Brand of Flutamide; Azupharma Brand of Flutamide; Cell pharm Brand of Flutamide; Chephasaar Brand of Flutamide; Chiron Brand of Flutamide; Ciclum Brand of Flutamide; Esparma Brand of Flutamide; Essex Brand of Flutamide; Fluta GRY; Fluta cell; Gry Brand of Flutamide; Hexal Brand of Flutamide; InibsaBrand of Flutamide; Ipsen Brand of Flutamide; Juta Brand of Flutamide; Kendrick Brand of Flutamide; Lemery Brand of Flutamide; Novo Flutamide; Novopharm Brand of Flutamide; PMS Flutamide; Pharmascience Brand of Flutamide; Prasfarma Brand of Flutamide; Q Pharm Brand of Flutamide; Schering Brand of Flutamide; Schering Plough Brand of Flutamide; TAD Brand of Flutamide; Tedec Meiji Brand of Flutamide; F 9397; F0663; Fluta 1A Pharma; Flutamide USP25; SCH13521; Sch 13521; Apo-Flutamide; Cebatrol, veterinary; Eulexin (TN); Fluta-GRY; Fluta-cell; Flutamida [INN-Spanish]; Flutamide(pubertal study); Flutamidum [INN-Latin]; NK-601; Novo-Flutamide; PMS-Flutamide; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; Q-Pharm Brand of Flutamide; Sch-13521; Schering-Plough Brand of Flutamide; Flutamide [USAN:BAN:INN]; Ham's F-12 medium; Eulexin, Flutamin, Drogenil,Flutamide; Flutamide (JAN/USP/INN); Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; M-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; M-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-(8CI); 1A Brand of Flutamide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; 4'-Nitro-3'-trifluoromethylisobutyramilide; 4'-Nitro-3'-trifluoromethylisobutyranilide; 4-Nitro-3-(trifluoromethyl)isobutyranilide; Flutamide (AR inhibitor)

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[1]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 3397
  ChEBI ID: CHEBI:5132
  CAS Number: CAS 13311-84-7
  TTD Drug ID: DMK0O7U
  VARIDT Drug ID: DR00846
  INTEDE Drug ID: DR0733
  ACDINA Drug ID: D00288

Molecule-Related Drug Atlas

Drug(s) Targeting Androgen receptor (AR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[15]
Darolutamide	DMV7YFT	Prostate cancer	2C82.0	Approved	[16]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[17]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[18]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[19]
Fludrocortisone	DMUDIR8	Addison disease	5A74.0	Approved	[20]
ARN-509	DMT81LZ	Acute myeloid leukaemia	2A60	Approved	[21]
Nilutamide	DMFN07X	Prostate cancer	2C82.0	Approved	[22]
Nandrolone	DMFWKG1	Osteoporosis	FB83.0	Approved	[23]
Fluoxymesterone	DMUHCF1	Breast cancer	2C60-2C65	Approved	[24]

Drug(s) Transported By Multidrug resistance-associated protein 1 (ABCC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[25]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[26]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[27]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[28]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[29]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[30]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[31]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[32]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[33]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[34]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[35]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[36]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[37]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[38]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[39]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[40]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[41]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[42]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[36]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[43]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[103]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[104]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[105]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[106]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[107]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[107]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[108]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[109]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[110]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[111]

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[44]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[45]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[46]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[47]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[48]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[41]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[50]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[51]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[52]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[117]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[117]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[117]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[114]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[118]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[115]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[119]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[120]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[121]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[116]

Drug(s) Metabolized By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[53]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[54]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[55]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[56]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[50]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[57]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[58]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[59]
Riboflavin	DM8YMWE	Acne vulgaris	ED80	Approved	[60]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[61]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[85]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[86]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[87]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[88]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[89]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[90]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[91]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[92]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[93]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[94]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[62]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[63]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[64]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[65]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[66]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[67]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[68]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[69]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[70]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[65]

Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[71]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[72]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[73]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[74]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[75]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[76]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[77]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[78]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[79]

Drug(s) Metabolized By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[80]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[55]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[50]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[58]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[59]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[81]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[82]
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[83]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[84]
Theophylline	DMRJFN9	Bronchitis	CA20	Approved	[83]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[95]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[96]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[97]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[98]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[84]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[82]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[99]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[100]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[101]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[102]

Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[104]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[112]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[106]
Chloramphenicol	DMFXEWT	Bacterial infection	1A00-1C4Z	Approved	[113]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[114]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[107]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[115]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[107]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[112]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[116]

Drug(s) Affected By 3-oxo-5-alpha-steroid 4-dehydrogenase 2 (SRD5A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[122]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[123]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[124]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[125]
Dutasteride	DMQ4TJK	Benign prostatic hyperplasia	GA90	Approved	[126]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[123]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[127]
Methyltestosterone	DMWLFGO	Advanced cancer	2A00-2F9Z	Approved	[7]
Finasteride	DMWV3TZ	Baldness, male pattern		Approved	[7]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[128]

Drug(s) Affected By Prostate-specific antigen (KLK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[129]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[130]
Selenium	DM25CGV	N. A.	N. A.	Approved	[131]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[132]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[133]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[134]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[135]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[136]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[137]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[138]

Drug(s) Affected By Proepiregulin (EREG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[139]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[10]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[140]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[10]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[10]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[141]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[142]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[143]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[144]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[10]

Drug(s) Affected By Transmembrane protease serine 2 (TMPRSS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[9]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[9]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[140]
Selenium	DM25CGV	N. A.	N. A.	Approved	[145]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[9]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[9]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[9]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[9]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[9]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[9]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[146]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[146]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[147]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[148]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[149]
Etidronic acid	DM1XHYJ	Bone Paget disease		Approved	[146]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[146]
Bromperidol	DM24XYQ	Schizophrenia	6A20	Approved	[146]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[150]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[151]

Drug(s) Affected By Interleukin-1 beta (IL1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[152]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[153]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[154]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[10]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[155]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[10]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[156]
Selenium	DM25CGV	N. A.	N. A.	Approved	[157]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[158]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[159]

Drug(s) Affected By Estrogen receptor (ESR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[160]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[161]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[162]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[163]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[164]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[165]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[166]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[167]
Procaine	DM4LSNE	Anaesthesia	9A78.6	Approved	[163]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[168]

Drug(s) Affected By Antileukoproteinase (SLPI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[10]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[10]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[140]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[10]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[10]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[10]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[10]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[169]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[10]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[10]

Drug(s) Affected By Protein S100-A8 (S100A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[8]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[170]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[171]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[171]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[172]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[173]
Halothane	DM80OZ5	Anaesthesia	9A78.6	Approved	[8]
Dicloxacillin	DM8EU0Z	Bacterial infection	1A00-1C4Z	Approved	[8]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[174]

Drug(s) Affected By Protein S100-A9 (S100A9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[8]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[175]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[170]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[171]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[171]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[176]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[177]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[173]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[178]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[123]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[179]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[180]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[181]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[182]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[183]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[184]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[185]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[186]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[187]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[185]

Drug(s) Affected By Hepatocyte growth factor receptor (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[188]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[189]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[10]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[10]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[10]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[190]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[142]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[10]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[191]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[190]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[192]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[193]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[194]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[101]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[195]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[153]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[10]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[155]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[196]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[10]

Drug(s) Affected By Gap junction alpha-1 protein (GJA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[197]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[176]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[198]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[199]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[200]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[201]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[202]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[197]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[203]
Griseofulvin	DMK54YG	Onychomycosis	EE12.1	Approved	[204]

Drug(s) Affected By Insulin-like growth factor-binding protein 3 (IGFBP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[205]
Selenium	DM25CGV	N. A.	N. A.	Approved	[206]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[207]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[208]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[143]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[171]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[209]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[210]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[211]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[212]

Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[213]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[214]
Methysergide	DM1EF73	Migraine	8A80	Approved	[215]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[216]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[217]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[215]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[142]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[218]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[219]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[220]

Drug(s) Affected By Bone morphogenetic protein 6 (BMP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[10]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[10]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[221]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[10]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[10]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[10]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[10]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[222]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[10]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[174]

Drug(s) Affected By Catenin beta-1 (CTNNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[223]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[224]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[225]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[226]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[227]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[228]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[229]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[230]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[231]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[232]

Drug(s) Affected By Prostaglandin G/H synthase 2 (PTGS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[233]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[234]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[235]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[236]
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[237]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[238]
Ibandronate	DM0QZBN	Hypercalcaemia	5B91.0	Approved	[239]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[129]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[10]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[240]

Drug(s) Affected By Tumor necrosis factor-inducible gene 6 protein (TNFAIP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[241]
Selenium	DM25CGV	N. A.	N. A.	Approved	[157]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[10]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[143]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[198]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[172]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[10]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[10]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[10]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[10]

Drug(s) Affected By Interleukin-24 (IL24)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[242]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[10]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[153]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[10]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[10]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[243]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[143]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[171]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[10]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[171]

Drug(s) Affected By Advanced glycosylation end product-specific receptor (AGER)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[244]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[245]
TRIENTINE	DMD2WPG	Inborn error of metabolism	5C50-5C59	Approved	[246]
Mebendazole	DMO14SG	Ascariasis	1F62	Approved	[247]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[248]
Estriol	DMOEM2I	Hormone deficiency	5A61.1	Approved	[248]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[249]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[250]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[248]

Drug(s) Affected By PTB-containing, cubilin and LRP1-interacting protein (PID1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[10]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[10]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[10]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[10]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[10]
Amikacin	DM5PDRB	Bacteremia	1A73	Approved	[10]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[10]
Promethazine	DM6I5GR	Hyperemesis gravidarum		Approved	[10]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[10]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[123]

Drug(s) Affected By Estrogen receptor beta (ESR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[129]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[251]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[252]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[253]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[254]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[255]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[256]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[257]
Mestranol	DMG3F94	Contraception	QA21	Approved	[258]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[259]

Drug(s) Affected By NACHT, LRR and PYD domains-containing protein 3 (NLRP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[152]
Selenium	DM25CGV	N. A.	N. A.	Approved	[157]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[169]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[260]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[261]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[245]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[262]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[263]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[264]
Atropine	DMEN6X7	Organophosphate poisoning	NE6Z	Approved	[8]

Drug(s) Affected By Homeobox protein Nkx-3.1 (NKX3-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[132]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[265]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[266]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[267]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[268]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[269]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[270]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[271]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[272]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[273]

Drug(s) Affected By Angiotensin-converting enzyme 2 (ACE2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Captopril	DM458UM	Chronic heart failure	BD1Z	Approved	[274]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[9]
Dantrolene	DM1D8XY	Hyperthermia	MG26	Approved	[9]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[9]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[9]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[9]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[9]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[9]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[9]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[9]

Drug(s) Affected By Cystine/glutamate transporter (SLC7A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[275]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[10]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[276]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[10]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[10]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[190]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[277]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[142]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[278]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[10]

Drug(s) Affected By Nuclear factor erythroid 2-related factor 2 (NFE2L2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[279]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[280]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[281]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[155]
Selenium	DM25CGV	N. A.	N. A.	Approved	[145]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[282]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[283]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[284]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[142]
Furazolidone	DM3P6V7	Diarrhea	ME05.1	Approved	[285]

Drug(s) Affected By Arylacetamide deacetylase (AADAC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[286]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[287]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[123]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[200]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[287]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[287]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[288]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[123]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[289]
Rifapentine	DMCHV4I	Pulmonary tuberculosis	1B10.Z	Approved	[289]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Antagonist	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[4]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[5]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[4]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[6]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[4]
Cytochrome P450 1B1 (CYP1B1)	DE9QHP6	CP1B1_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3-oxo-5-alpha-steroid 4-dehydrogenase 2 (SRD5A2)	OTTG0NFD	S5A2_HUMAN	Gene/Protein Processing	[7]
Advanced glycosylation end product-specific receptor (AGER)	OTPY0IH7	RAGE_HUMAN	Gene/Protein Processing	[8]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[9]
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[10]
Arylacetamide deacetylase (AADAC)	OT8VACT2	AAAD_HUMAN	Biotransformations	[11]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[12]
Bone morphogenetic protein 6 (BMP6)	OT9WN536	BMP6_HUMAN	Gene/Protein Processing	[10]
Catenin beta-1 (CTNNB1)	OTZ932A3	CTNB1_HUMAN	Protein Interaction/Cellular Processes	[13]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Gene/Protein Processing	[10]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[14]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6943).
• [2] Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
• [3] The multidrug resistance-associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. Toxicol Lett. 2003 Apr 30;142(1-2):61-70.
• [4] Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
• [5] Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
• [6] Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos. 1997 Nov;25(11):1298-303.
• [7] Effects of various pesticides on human 5alpha-reductase activity in prostate and LNCaP cells. Toxicol In Vitro. 2007 Apr;21(3):502-8.
• [8] Prediction of drug-induced liver injury using keratinocytes. J Appl Toxicol. 2017 Jul;37(7):863-872. doi: 10.1002/jat.3435. Epub 2017 Jan 31.
• [9] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [10] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [11] Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. Drug Metab Dispos. 2012 Apr;40(4):671-9. doi: 10.1124/dmd.111.043067. Epub 2011 Dec 29.
• [12] PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
• [13] Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations. Chem Biol Interact. 2011 Feb 1;189(3):177-85. doi: 10.1016/j.cbi.2010.11.008. Epub 2010 Nov 25.
• [14] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [15] Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [17] Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
• [18] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [19] Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
• [20] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [21] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [22] CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
• [23] Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
• [24] An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73.
• [25] The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
• [26] Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
• [27] Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
• [28] Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
• [29] Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
• [30] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [31] ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
• [32] Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
• [33] Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
• [34] Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
• [35] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [36] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [37] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [38] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [39] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [40] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [41] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [42] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [43] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [44] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [45] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [46] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [47] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [48] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [49] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [50] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [51] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [52] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [53] Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
• [54] Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
• [55] Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
• [56] Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
• [57] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [58] A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
• [59] Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
• [60] Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
• [61] Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
• [62] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [63] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [64] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [65] Drug Interactions Flockhart Table
• [66] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [67] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [68] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [69] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [70] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [71] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [72] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [73] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [74] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [75] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [76] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [77] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [78] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [79] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [80] Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
• [81] Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008 Jul;30(7):1283-9.
• [82] Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
• [83] Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
• [84] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [85] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [86] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [87] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [88] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [89] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [90] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [91] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [92] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [93] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [94] The inducibility of human cytochrome P450 1A by environmental-relevant xenobiotics in the human hepatoma derived cell line HepG2. Environ Toxicol Pharmacol. 2009 Nov;28(3):370-8.
• [95] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [96] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [97] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [98] In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
• [99] Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
• [100] Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
• [101] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [102] Red clover aryl hydrocarbon receptor (AhR) and estrogen receptor (ER) agonists enhance genotoxic estrogen metabolism. Chem Res Toxicol. 2017 Nov 20;30(11):2084-2092.
• [103] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [104] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [105] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [106] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [107] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [108] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [109] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [110] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [111] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [112] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [113] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [114] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [115] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [116] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [117] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [118] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [119] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [120] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [121] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [122] Effects of low dose treatment of tributyltin on the regulation of estrogen receptor functions in MCF-7 cells. Toxicol Appl Pharmacol. 2013 Jun 1;269(2):176-86.
• [123] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [124] Propofol suppresses proliferation, migration, invasion, and tumor growth of liver cancer cells via suppressing cancer susceptibility candidate 9/phosphatase and tensin homolog/AKT serine/threonine kinase/mechanistic target of rapamycin kinase axis. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271211065972. doi: 10.1177/09603271211065972.
• [125] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [126] Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment. J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):129-40.
• [127] Molecular interactions of progesterone derivatives with 5 alpha-reductase types 1 and 2 and androgen receptors. Steroids. 2010 Jul;75(7):499-505.
• [128] Examining the genomic influence of skin antioxidants in vitro. Mediators Inflamm. 2010;2010.
• [129] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [130] Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. Clin Chim Acta. 2001 Oct;312(1-2):213-9. doi: 10.1016/s0009-8981(01)00626-x.
• [131] Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
• [132] Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14. doi: 10.1093/carcin/22.3.409.
• [133] EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24.
• [134] Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate. 2007 Aug 1;67(11):1152-62. doi: 10.1002/pros.20585.
• [135] Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.
• [136] An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003 Mar 24;88(6):822-7. doi: 10.1038/sj.bjc.6600817.
• [137] Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
• [138] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [139] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [140] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [141] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [142] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [143] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [144] Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
• [145] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [146] Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
• [147] Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
• [148] Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
• [149] Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
• [150] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [151] Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
• [152] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [153] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [154] Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
• [155] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [156] (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
• [157] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [158] Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
• [159] Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis. 2006 Apr;11(4):573-9. doi: 10.1007/s10495-006-4919-3.
• [160] Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology. 2003 Jun;144(6):2425-36. doi: 10.1210/en.2002-221054.
• [161] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [162] Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006 Mar;96(2):131-46. doi: 10.1007/s10549-005-9070-2. Epub 2005 Oct 27.
• [163] Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. Odontology. 2013 Jan;101(1):43-51.
• [164] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [165] Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
• [166] Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol. 2001 Sep;60(3):595-602.
• [167] Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer. 2007 Apr 23;96(8):1204-15. doi: 10.1038/sj.bjc.6603705. Epub 2007 Mar 27.
• [168] Prediction of the combined effects of multiple estrogenic chemicals on MCF-7 human breast cancer cells and a preliminary molecular exploration of the estrogenic proliferative effects and related gene expression. Ecotoxicol Environ Saf. 2018 Sep 30;160:1-9. doi: 10.1016/j.ecoenv.2018.05.025. Epub 2018 May 21.
• [169] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [170] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [171] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [172] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [173] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [174] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [175] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [176] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [177] Retinoic acid and hydroquinone induce inverse expression patterns on cornified envelope-associated proteins: implication in skin irritation. J Dermatol Sci. 2014 Nov;76(2):112-9. doi: 10.1016/j.jdermsci.2014.08.003. Epub 2014 Aug 26.
• [178] 1 alpha,25-(OH)2 vitamin D3 enhances expression of the genes encoding Ca(2+)-binding proteins MRP-8 and MRP-14. Am J Physiol. 1992 Jan;262(1 Pt 1):C235-42. doi: 10.1152/ajpcell.1992.262.1.C235.
• [179] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [180] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [181] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [182] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [183] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [184] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [185] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [186] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [187] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [188] ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
• [189] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [190] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [191] All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
• [192] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [193] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [194] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [195] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [196] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [197] Inhibition of estrogen receptor reduces connexin 43 expression in breast cancers. Toxicol Appl Pharmacol. 2018 Jan 1;338:182-190. doi: 10.1016/j.taap.2017.11.020. Epub 2017 Nov 24.
• [198] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [199] Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83.
• [200] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [201] Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
• [202] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [203] Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment. Am J Hypertens. 2006 Feb;19(2):129-35. doi: 10.1016/j.amjhyper.2005.08.020.
• [204] The anti-mitotic drug griseofulvin induces apoptosis of human germ cell tumor cells through a connexin 43-dependent molecular mechanism. Apoptosis. 2013 Apr;18(4):480-91. doi: 10.1007/s10495-012-0800-8.
• [205] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [206] Selenium is critical for cancer-signaling gene expression but not cell proliferation in human colon Caco-2 cells. Biofactors. 2007;31(3-4):155-64. doi: 10.1002/biof.5520310302.
• [207] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [208] Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Mol Cell Biochem. 2010 Nov;344(1-2):173-84. doi: 10.1007/s11010-010-0540-4. Epub 2010 Jul 25.
• [209] Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008 Oct;7(10):1607-18.
• [210] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [211] Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells. Oncol Rep. 2016 Sep;36(3):1233-42. doi: 10.3892/or.2016.4944. Epub 2016 Jul 15.
• [212] DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab. 2006 May;290(5):E952-60. doi: 10.1152/ajpendo.00451.2005. Epub 2005 Dec 20.
• [213] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [214] 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
• [215] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [216] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [217] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [218] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [219] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [220] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [221] Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. Mol Cell Neurosci. 2007 Mar;34(3):310-23. doi: 10.1016/j.mcn.2006.11.008. Epub 2006 Dec 28.
• [222] 2,3,7,8-tetrachlorodibenzo-p-dioxin augments the modulation of gene expression mediated by the thyroid hormone receptor. Toxicol Appl Pharmacol. 2004 Feb 1;194(3):201-10. doi: 10.1016/j.taap.2003.09.010.
• [223] Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
• [224] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [225] Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008 Mar 31;583(1):26-31. doi: 10.1016/j.ejphar.2007.12.034. Epub 2008 Feb 5.
• [226] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [227] Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012 Jan 2;348(1):260-9. doi: 10.1016/j.mce.2011.09.002. Epub 2011 Sep 6.
• [228] Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res. 2008 Nov;32(11):1674-83. doi: 10.1016/j.leukres.2008.03.039. Epub 2008 May 15.
• [229] Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006 Oct 19;25(49):6447-56. doi: 10.1038/sj.onc.1209658. Epub 2006 Jul 31.
• [230] Benzene metabolite hydroquinone induces apoptosis of bone marrow mononuclear cells through inhibition of -catenin signaling. Toxicol In Vitro. 2018 Feb;46:361-369. doi: 10.1016/j.tiv.2017.08.018. Epub 2017 Sep 5.
• [231] Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro. 2017 Apr;40:324-335. doi: 10.1016/j.tiv.2017.01.019. Epub 2017 Feb 2.
• [232] Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
• [233] Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. Toxicol Lett. 2015 Jul 16;236(2):75-81.
• [234] Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
• [235] Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. Br J Nutr. 2006 Nov;96(5):811-9.
• [236] COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
• [237] Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
• [238] Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
• [239] Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
• [240] A2E selectively induces cox-2 in ARPE-19 and human neural cells. Curr Eye Res. 2006 Mar;31(3):259-63.
• [241] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [242] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [243] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [244] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [245] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [246] Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-B pathway in a transgenic mouse model of Alzheimer's disease. Antioxid Redox Signal. 2013 Dec 10;19(17):2024-39. doi: 10.1089/ars.2012.5158. Epub 2013 May 3.
• [247] Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury. Toxicol Lett. 2014 Jul 3;228(1):13-24. doi: 10.1016/j.toxlet.2014.04.005. Epub 2014 Apr 15.
• [248] Differential effect of estrogen receptor alpha and beta agonists on the receptor for advanced glycation end product expression in human microvascular endothelial cells. Biochim Biophys Acta. 2005 Sep 30;1745(3):300-9. doi: 10.1016/j.bbamcr.2005.03.012. Epub 2005 Apr 12.
• [249] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [250] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [251] Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother. 2010 Feb;64(2):88-92. doi: 10.1016/j.biopha.2009.06.010. Epub 2009 Oct 23.
• [252] Quercetin exerts bidirectional regulation effects on the efficacy of tamoxifen in estrogen receptor-positive breast cancer therapy: An in vitro study. Environ Toxicol. 2020 Nov;35(11):1179-1193. doi: 10.1002/tox.22983. Epub 2020 Jun 12.
• [253] Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. Toxicology. 2001 Sep 14;166(1-2):79-89. doi: 10.1016/s0300-483x(01)00437-1.
• [254] Estrogenic effects of natural and synthetic compounds including tibolone assessed in Saccharomyces cerevisiae expressing the human estrogen alpha and beta receptors. FASEB J. 2006 Jul;20(9):1552-4. doi: 10.1096/fj.05-5413fje. Epub 2006 May 23.
• [255] Comparison of relative binding affinities to fish and mammalian estrogen receptors: the regulatory implications. Toxicol Lett. 2010 Feb 15;192(3):298-315. doi: 10.1016/j.toxlet.2009.11.004. Epub 2009 Nov 12.
• [256] Screening for estrogen and androgen receptor activities in 200 pesticides by in vitro reporter gene assays using Chinese hamster ovary cells. Environ Health Perspect. 2004 Apr;112(5):524-31. doi: 10.1289/ehp.6649.
• [257] Valproic acid and its derivatives enhanced estrogenic activity but not androgenic activity in a structure dependent manner. Reprod Toxicol. 2013 Dec;42:49-57. doi: 10.1016/j.reprotox.2013.07.019. Epub 2013 Jul 26.
• [258] Relationship between estrogen receptor-binding and estrogenic activities of environmental estrogens and suppression by flavonoids. Biosci Biotechnol Biochem. 2002 Jul;66(7):1479-87. doi: 10.1271/bbb.66.1479.
• [259] Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
• [260] AS3MT facilitates NLRP3 inflammasome activation by m(6)A modification during arsenic-induced hepatic insulin resistance. Cell Biol Toxicol. 2023 Oct;39(5):2165-2181. doi: 10.1007/s10565-022-09703-7. Epub 2022 Feb 28.
• [261] Hydroquinone triggers pyroptosis and endoplasmic reticulum stress via AhR-regulated oxidative stress in human lymphocytes. Toxicol Lett. 2023 Mar 1;376:39-50. doi: 10.1016/j.toxlet.2023.01.005. Epub 2023 Jan 13.
• [262] Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study. Arch Toxicol. 2022 Apr;96(4):1075-1087. doi: 10.1007/s00204-022-03245-x. Epub 2022 Feb 22.
• [263] Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.
• [264] Pterostilbene attenuates RIPK3-dependent hepatocyte necroptosis in alcoholic liver disease via SIRT2-mediated NFATc4 deacetylation. Toxicology. 2021 Sep;461:152923. doi: 10.1016/j.tox.2021.152923. Epub 2021 Aug 30.
• [265] Transcriptional regulation of the homeobox gene NKX3.1 by all-trans retinoic acid in prostate cancer cells. J Cell Biochem. 2006 Dec 1;99(5):1409-19. doi: 10.1002/jcb.21020.
• [266] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [267] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [268] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [269] Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Mol Cancer Ther. 2017 Aug;16(8):1521-1530. doi: 10.1158/1535-7163.MCT-16-0912. Epub 2017 May 12.
• [270] Effects of 9-cis retinoic acid on human homeobox gene NKX3.1 expression in prostate cancer cell line LNCaP. Asian J Androl. 2006 Jul;8(4):435-41. doi: 10.1111/j.1745-7262.2006.00171.x.
• [271] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [272] A role for DNA methylation in regulating the growth suppressor PMEPA1 gene in prostate cancer. Epigenetics. 2007 Apr-Jun;2(2):100-9.
• [273] The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 2009 Sep 4;284(36):24306-19.
• [274] Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. Clin Pharmacol Ther. 2007 Aug;82(2):187-96. doi: 10.1038/sj.clpt.6100214. Epub 2007 May 2.
• [275] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [276] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [277] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [278] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [279] Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
• [280] Protective role of HO-1 for alcohol-dependent liver damage. Dig Dis. 2010;28(6):792-8. doi: 10.1159/000324287. Epub 2011 Apr 27.
• [281] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [282] Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease. J Neurosci. 2016 Jun 8;36(23):6332-51. doi: 10.1523/JNEUROSCI.0426-16.2016.
• [283] Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
• [284] P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
• [285] P21(Waf1/Cip1) plays a critical role in furazolidone-induced apoptosis in HepG2 cells through influencing the caspase-3 activation and ROS generation. Food Chem Toxicol. 2016 Feb;88:1-12. doi: 10.1016/j.fct.2015.12.004. Epub 2015 Dec 11.
• [286] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [287] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [288] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [289] Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol. 2011 Dec 1;82(11):1747-56.